跳至主要内容
临床试验/CTRI/2022/06/043053
CTRI/2022/06/043053已完成2/3 期

A comparative clinical study to evaluate the efficacy of yapana basti and nasya along with shirobasti followed by kauncha paka in the management of kampavata with special reference to Parkinson’s disease (PD).

National Institute of Ayurveda1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年6月15日最近更新:

试验速览

阶段
2/3 期
状态
已完成
入组人数
30
试验地点
1
主要终点
Assessment of changes will be assessed on the basis of UPDRS

研究概览

简要总结

Parkinson’s disease (PD) is a group of progressive neurodegenerative disorders characterized by tremor, akinesia, bradykinesia, muscular rigidity, abnormalities of posture, impairment of postural control and balance, abnormalities of gait, dysphonia, dysarthria and stammer.

In Ayurveda the Vata Dosha which is the motivator and controller of other two Doshai.e.,Pitta and Kapha, is responsible for almost all types of diseases. All motor and sensory functions are control by Vata Dosha. According the Ayurveda Major neurological problems come under Vata Vyadhi, Kampavata is one of them. Kampavata is that condition caused by Vata in which all the part of the body including the head will have tremors.

Ayurveda takes a unique approach to the management of Vata Vyadhi (Kampa vata/PD) with a special emphasis on eliminating their cause by Panchakarma. Panchakarma procedures like different types of Snehana, Swedana , Vamana, Virechana, Basti and Nasya Karma are especially indicated in the treatment of neurological diseases. Besides a special treatment like Shirobasti, Shirodhara, Nasya and Basti karma are indicated in such diseases.

GROUPING:- After the complete examination and investigation, all the 30 patients will be divided into two groups (15 patients in each group) detail as below-ï‚· Group A- Tritiya Baladi Yapana Basti along with Shirobasti for 16 days followed by Kauncha Paka 10 gm twice a day after meal for 15 days. ï‚· Group B- Nasya along with Shirobasti for 16 days followed by Kauncha Paka  10 gm twice a day after meal for 15 days.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
40.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Patients between 40-70 years of age.
  • Patients with clinical signs and symptoms of Kampavata/ PD.
  • Patients of either sex irrespective of their occupation, religion and socio-economic status.
  • Patients of Kampavata/PD who are fit for Shirobasti , Basti and Nasya.
  • Patients willing to participate for interventional study.

排除标准

  • Patients with severe systemic disorders as Uncontrolled Hypertension, Cardiac Problem, Uncontrolled Diabetes Mellitus, Tuberculosis, Leprosy, Paralysis, malignant disease etc.
  • Patients unfit for Shirobasti , Basti and Nasya.

结局指标

主要结局

Assessment of changes will be assessed on the basis of UPDRS

时间窗: Assessment will be done at | Day 0, Day 16, Day 31 and after follow-up of 15 days

(Unified Parkinson’s disease Rating Scale) (modified) before and after the treatment.

时间窗: Assessment will be done at | Day 0, Day 16, Day 31 and after follow-up of 15 days

次要结局

  • Assessment of changes in following specific signs and symptoms of Kampavata(1 kampa)

研究者

申办方类型
Government medical college

研究点 (1)

Loading locations...

相似试验